Report reviews new drugs’ potential impact on future drug spending in Canada
The Patented Medicine Prices Review Board has released an extensive listing of new medicines in the late stages of clinical evaluation that it predicts may “significantly impact clinical practice or drug...To view the full article, register now.
Already a subscriber? Click here to view full article